A method for separating and extracting mesenchymal stem cells from human umbilical cord tissue. The method uses healthy neonatal umbilical cord tissue; after cleaning and disinfection, mechanically pulverising same, separating the outer layer of amniotic membrane, and after treating with erythrocyte lysate, carrying out suspension culture in a serum-free culture medium. Replacing the liquid every 3-5 days; after the plate adherence rate reaches 30-70%, carrying out trypsin digestion, and then collecting the cells by centrifugation for passage amplification, until the rate of confluence of the cells reaches over 90% confluence, thereby obtaining high purity umbilical cord mesenchymal stem cells.
Methods are disclosed for forming bone and/or cartilage in an avian subject. The methods include administering to the avian subject a therapeutically effective amount of a composition comprising avian mesenchymal stem cells and a hydrogel that supports the differentiation of the avian mesenchymal stem cells into cells of an osteogenic and/or condrogenic lineage. In some embodiments, methods are disclosed for repairing a bone defect and preventing infection, such as that associated bone fracture, in an avian subject. The methods include administering locally to the bone defect a composition comprising a therapeutically effective amount of avian mesenchymal stem cells and a hydrogel, such as a methacrylated gelatin hydrogel.
Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.
The present invention provides compositions and methods of preparing airway cells. In one aspect, an epithelial airway cell derived from an induced pluripotent stem (iPS) cell characterized by expression of airway cell surface markers and an ability to proliferate is described. In another aspect, methods of differentiating an iPS into an epithelial airway cell is provided. Engineered lungs, methods of making such engineered lungs comprising the epithelial airway cells and treating respiratory disorders are also disclosed.
The present invention provides a method for manufacturing ciliary margin stem cells differentiated from pluripotent stem cells, the method comprising step (1) and/or step (2) below: (1) a step for obtaining retinospheres by suspension culturing of cells obtained from cell aggregates comprising ciliary margin-like structures differentiated from pluripotent stem cells; and (2) a step for isolating stage specific embryonic antigen-1-positive cells from cells obtained from cell aggregates comprising ciliary margin-like structures differentiated from pluripotent stem cells. The present invention makes it possible to manufacture efficiently and with high purity ciliary margin stem cells with the ability to differentiate to retinal cells comprising retinal layer-specific neurons and the ability to self-replicate.
The present invention relates to a cell culturing system using multiple stimuli and, more particularly, to a cell culturing system that includes a culture medium pumping unit and a clamp unit, and is capable of culturing cells by applying multiple stimuli such as shear stress due to the flow of a culture medium and pressure from periodic contracting and relaxing to cells being cultured inside a tube. The cell culturing system according to the present invention provides an environment similar to an in vivo environment and shows effects in accelerating the differentiation of stem cells into myocardial cells.
The invention discloses a method for in vitro diagnosing a pancreas or colon cancer tissue specimen wherein the specimen is analysed for the presence or absence of the ectodomain of EpCAM (EpEX) as well as for the presence or absence of the intracellular domain of EpCAM (EpICD).
Provided is an inducing agent for megakaryocytes and/or platelets from pluripotent stem cells, the inducing agent being useful in treating diseases involving thrombopenia. A method for producing megakaryocytes and/or platelets, the method comprising: separating hematopoietic progenitor cells and cells that form a septum of a net-like structure produced by pluripotent stem cells, in the presence of a compound represented by formula (I) (R1-R7, W, X, Y, Z, Ar1, and n in the formula are defined in the specification), a tautomer of the compound, a prodrug, a pharmaceutically acceptable salt of these, or a solvate of these compounds; culturing the resulting hematopoietic progenitor cells in vitro; and differentiating the same into megakaryocytes and/or platelets.
A thiol-yne polymeric material and methods for producing said polymers are disclosed. The material is produced by the radically mediated polymerization of monomers having alkyne and thiol functional groups. The alkyne moiety, internal or terminal, may react with one or two thiols. Degradable monomers may be used to form degradable polymers.
A method of treating increased non-LTR retrotransposition in a cell. The method includes exposing a neural cell to a retrotransposition inhibitor in an amount sufficient to decrease the non-LTR retrotransposition in the neural cell or a progeny of the neural cell. In various embodiments, the non-LTR retrotransposition involves at least one Ll retrotransposon. Also provided is a method of assaying retrotransposition in neural cells. The method includes sorting synchronized neural cells of the same genetic background into single neural cells, and subjecting one or more of the sorted single neural cells to quantitative polymerase chain reaction amplification of at least one retrotransposon. In addition, a method of identifying an inhibitor of retrotransposition and a identifying a neural condition associated with non-LTR retrotransposition are provided.